

sanofi aventis

To the attention of

Dr Eric Abadie – CHMP chairman

recherche & développement

**European Medicine Agency - EMA,
7, Westferry Circus, Canary Wharf
London, E14 4HB
United Kingdom**

Chilly Mazarin, 18 December 2009

**Subject: Request for withdrawal of Marketing Authorisation Application for SLIWENS™
(Eplivanserin - SR46349) 5 mg film-coated tablets – EMA/H/C/001102**

Dear Dr Abadie,

I would like to inform you that, at this point of time, Sanofi-Aventis has taken the decision to withdraw the application for Marketing Authorisation of SLIWENS (eplivanserin – SR46349), 5 mg film-coated tablets, which was intended to be used for the treatment of chronic insomnia characterized by difficulties with sleep maintenance as measured by duration and number of nocturnal awakenings.

The applicant decided not to pursue the registration based on feedback from regulatory agencies.

We reserve the right to make further submissions at a future date in this or other therapeutic indications.

I agree for this letter to be published on the EMEA website.

Sincerely yours,